RRC ID 42979
Author Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, Naritomi K.
Title Midkine as a novel target for antibody therapy in osteosarcoma.
Journal Biochem Biophys Res Commun
Abstract Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P<0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas.
Volume 358(3)
Pages 757-62
Published 2007-7-6
DOI 10.1016/j.bbrc.2007.04.183
PII S0006-291X(07)00914-X
PMID 17506984
MeSH Adolescent Adult Antibodies / chemistry* Bone Neoplasms / therapy* Cell Line, Tumor Cell Proliferation Child Cytokines / chemistry* Cytokines / pharmacology* Gene Expression Regulation, Neoplastic* Humans Immunohistochemistry Immunotherapy / methods* Midkine Osteosarcoma / therapy* Prognosis Retrospective Studies
IF 2.985
Times Cited 23
WOS Category BIOPHYSICS BIOCHEMISTRY & MOLECULAR BIOLOGY
Resource
Human and Animal Cells